Results of Sacral Neuromodulation Therapy for Urinary Voiding Dysfunction: Outcomes of a Prospective, Worldwide Clinical Study
Purpose
This 5-year, prospective, multicenter trial evaluated the long-term safety and efficacy of sacral neuromodulation in patients with refractory urge incontinence, urgency frequency and retention.
Materials and Methods
A total of 17 centers worldwide enrolled 163 patients (87% female). Following test stimulation 11 patients declined implantation and 152 underwent implantation using InterStim®. Of those treated with implantation 96 (63.2%) had urge incontinence, 25 (16.4%) had urgency frequency and 31 (20.4%) had retention. Voiding diaries were collected annually for 5 years. Clinical success was defined as 50% or greater improvement from baseline in primary voiding diary variable(s).
Results
Data for all implanted cases were reported. For patients with urge incontinence mean leaking episodes per day decreased from 9.6 ± 6.0 to 3.9 ± 4.0 at 5 years. For patients with urgency frequency mean voids per day decreased from 19.3 ± 7.0 to 14.8 ± 7.6, and mean volume voided per void increased from 92.3 ± 52.8 to 165.2 ± 147.7 ml. For patients with retention the mean volume per catheterization decreased from 379.9 ± 183.8 to 109.2 ± 184.3 ml, and the mean number of catheterizations decreased from 5.3 ± 2.8 to 1.9 ± 2.8. All changes were statistically significant (p <0.001). No life threatening or irreversible adverse events occurred. In 102 patients 279 device or therapy related adverse events were observed. At 5 years after implantation 68% of patients with urge incontinence, 56% with urgency frequency and 71% with retention had successful outcomes.
Conclusions
This long-term study demonstrates that InterStim therapy is safe and effective for restoring voiding in appropriately selected cases refractory to other forms of treatment.
Key Words: electric stimulation therapy, urination disorders, urinary bladder
Abbreviations and Acronyms: AE, adverse event, FDA, Food and Drug Administration, INS, implantable neurostimulator, PAS, post approval study, PNE, percutaneous nerve evaluation, SNM, sacral neuromodulation, UF, urgency frequency, UI, urge incontinence
Study received approval from all ethical committees.
See Editorial on page 1844. For another article on a related topic see page 2203.
Editor’s Note: This article is the third of 5 published in this issue for which category 1 CME credits can be earned. Instructions for obtaining credits are given with the questions on pages 2226 and 2227.
PII: S0022-5347(07)01768-5
doi:10.1016/j.juro.2007.07.032
© 2007 American Urological Association. Published by Elsevier Inc. All rights reserved.
Refers to article:
- Neuromodulation and the Urinary Tract—Are We Over the Rainbow or Have We Simply Stepped Through the Looking Glass? , 14 September 2007
- Aldose Reductase Inhibitor ONO-2235 Restores the Alterations of Bladder Nerve Growth Factor and Neurotrophin Receptor p75 Genetic Expression in Streptozotocin Induced Diabetic Rats , 17 September 2007

